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A B S T R A C T
Introduction: The development of evidence-based clinical practice guidelines (CPGs) in traditional
medicine (TM) is an ongoing challenge as it is unique area. This study describes a uniﬁed platform with
Preferred Reporting Items for the Development of Evidence-based CPGs in TM (PRIDE-CPG-TM), which
has been successfully used by the evidence-based CPGs committee for TM.
Methods: Initially we searched the literature and CPG handbooks, collected items from methodology
references and drew on experiences gained from Korean medical physicians and methodology experts. A
group of experts subsequently edited drafts of the items, identiﬁed one or more examples of good
reporting for each item, and developed text that explained the rationale and discussed relevant evidence.
Face to face meetings were held with experts to ﬁnalize the items with the most extensive elaboration.
Results: The PRIDE-CPG-TM, in the form of a checklist and description of items with TM approach and TM
examples, were designed to improve the reporting of CPG in TM and thereby facilitate their interpretation
and replication. The PRIDE-CPG-TM included 5 domains and 40 items. The items pertain to the
development methodology (22 items), Overview of diseases and symptoms (6 items), Recommendations
(4 items), Implementation and dissemination (5 items) and others (3 items).
Conclusions: The completeness of CPG descriptions in TM is very poor. Therefore, a complete description
of the recommendations for TM in CPGs is necessary for physicians to implement the recommendations
in clinical practice areas. The PRIDE-CPG-TM will provide useful guidance for TM developers in the
development of evidence-based CPGs.
ã 2016 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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The U.S. Institute of Medicine (IOM) deﬁnes clinical practice
guidelines (CPG) as “statements that include recommendations
intended to optimize patient care that are informed by a systematic
review (SR) of evidence and an assessment of the beneﬁts and
harms of alternative care options” [1] and have become an
important vehicle for inﬂuencing clinical practice change [2].
CPG development processes vary substantially, and many
developed guidelines do not meet the basic quality criteria, which
should be precise and rigorous to ensure that the results are
reproducible and not vague [3]. Standards for CPG development
may help organisations ensure that recommendations are
evidence-based and may help users identify high-quality CPGs.
As a result of the lack of high quality evidence and understanding of
evidence-based medicine (EBM), the scientiﬁc validity of tradi-
tional medicine (TM) is more challenged than the westernarticle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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acceptability of CPG in TM because of the variation in the quality of
randomzed clinical trial (RCT)’s quality. This issue is complicated
by the fact that recommendations in TM have insufﬁcient evidence
to recommend for or against the TM.
In East-Asian countries, 80% of the population depends on TM
for primary health care, and 70–80% of the population in many
developed countries has used some form of alternative or
complementary medicine (CAM) [5]. Therefore, the development
and application of CPGs using an evidence-based approach have
been the agenda and have rapidly developed worldwide. South
Korea has maintained a dual healthcare delivery system that
incorporates both traditional Korean and Western medicine. The
development of CPGs was initiated approximately 15 years ago and
resulted in an increased interest in the development of CPGs in
healthcare [6]. TM in Korea remains in the beginning stage of
development. Currently, only 17 CPGs are available regarding TM
and the reporting of the CPGs is very unclear. Thus, many CPGs in
TM are developed based on consensus based CPGs.
There are many formal reporting guidelines to improve the
quality of scientiﬁc publications by promoting transparent and
accurate reporting and enabling readers to better understand the
design, conduct, analysis and ﬁndings of the research via the
EQUATOR (Enhancing the QUAlity and Transparency Of health
Research) Network [7]. Additionally, international TM researchers
have developed a set of recommendations for improving the
reporting of interventions in parallel group trials of acupuncture
[8] and herbal medicine [9].
The Korean medical world has previously developed the
STAndard Reporting Items for clinical Guidelines (STARIGs) [10]
and translated the Appraisal of Guideline Research & Evaluation II
(AGREE 2.0) for the Korean model of CPGs development [11],
education and dissemination to advance the standard of CPGs.
There are insufﬁcient examples or toolkits; however, several tools
or handbooks for guidelines exist. In addition, the guidance
regarding TM for guideline development is lacking for embodying
the characteristics of TM and understanding of TM interventions
requires a detailed description of the interventions and diagnosis.
Because of the unique features of TM interventions, reporting
guideline is needed.
There are some existing international guidance for CPG like
GRADE, IOM standard, GIN standards, Guideline 2.0 and WHO
standards. To the best of our knowledge, no study has developed
reporting guidelines for CPGs of TM based on EBM; however, CPG
development is rapidly researched in the TM or CAM community.
With the existence of references to guideline methodology, the key
rationale for having an extra CPG reporting guideline is to cover
areas unique to TM which are not covered by these references.
Therefore, we aimed to develop proper and important reporting
guidelines with key considerations for CPGs in TM. The main
motivation for the development of the PRIDE-CPG-TM is to
facilitate the development and publication of high quality CPGs
for TM.
2. Methods
2.1. Development process
We developed PRIDE-CPG-TM in 3 phases that included: pre-
meeting item generation, face to face consensus meeting, and then
a draft report circulated to invited experts to ensure that it
accurately represented decisions made during development
process.The project of PRIDE-CPG-TM for CPG in TM led by
collaboration of researchers, methodologists, CPG developers,
funders and had many face to face meeting to conclude the ﬁnalitems. Specially, methodologist led the identiﬁed items that
facilitate SR.
Five experts who were experienced SRs were contacted to help
in the development of the CPG and to extract the items and
examples. The development of PRIDE-CPG-TM was based on two
concepts. The ﬁrst concept included a comprehensive search for
published guidance or checklists for the reporting of CPGs using an
evidence-based approach and extracted the methodological items;
the second concept addressed how and to what extent TM issues
comprised pattern identiﬁcation, individualized intervention and
the experiences of clinical experts regarding the effective ways to
develop and implement the reporting guidelines for CPG. We
addressed TM issues not covered by the existing international
guidance. The PRIDE-CPG-TM development process is shown in
Fig. 1.
2.2. Literature search
We systematically searched the literature and guideline hand-
books or checklists and collected information on the methods and
reporting of the included CPGs from inception to March 2014.
PubMed was searched as an international database to retrieve
references. Moreover, other sources were browsed, including
International speciﬁc public databases for CPGs, the National
Guideline Clearinghouse (NGC), the Guideline International
Network (GIN), including the following Korean Guideline clear-
inghouse (KGC), and the Korean Medical Guideline Information
Centre (KoMGi). We selected and reviewed handbooks regarding
the methodology of developing the evidence-based CPG and
extracted the examples from domestic and international CPGs.
2.3. Item and example extraction
From each included handbook or guideline, a content analysis
was conducted to identify domains, and items of PRIDE-CPG-TM
which we needed to be modiﬁed were nominated, referring to
included handbooks or guidelines and then items were grouped
into these domains based on the questions or items from
checklists/frameworks (unit of analysis). The included examples
in this guideline were extracted from original reports of CPGs. Our
research team attempted to understand developers in the TM ﬁeld
were excerpts from the CPGs associated with TM.
2.4. Draft reporting guidelines
A group of experts edited drafts of the items, identiﬁed one or
more examples of good reporting for each item, and developed text
that explained the rationale and discussed the relevant evidence
with TM.
2.5. Composition and content rationale
PRIDE-CPG-TM was composed of 5 domains, including devel-
opment methodology, Overview of diseases/symptoms, Recom-
mendation, implementation and dissemination and others; 40
items were included for examination according to the description
order that may be listed in CPGs development.
The speciﬁc contents of the items are composed with
explanations and examples to facilitate the developer’s under-
standing. PRIDE-CPG-TM is a development guide that may be
applied in the De Novo process, which is a method of developing
CPGs through the steps of analysis, composition and summarisa-
tion, following the assessment of the quality of the evidence
selected, according to the methodology of SR, when CPGs have not
been previously developed for a key question.
Fig. 1. The process of development of PRIDE-CPG-TM in TM.
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We invited two experts who were experienced CPG develop-
ment and TM clinical setting via email, which outlined the items,
likely development and selection of items of validity evidence and
evaluation of the suitability.
3. Results
A comprehensive checklist of items were systematically
compiled with examples of the guidelines linked to relevant
resources and tools that CPG developers could consider, and which
would thereby facilitate their interpretation and replication. Seven
handbooks for CPG developers [10–16] [Table 1] and fourteen CPGs
for the extraction of examples [17–30] were included for CPG
developers in the TM area [Table 2]. Finally, the PRIDE-CPG-TM
proposed 5 items and 40 sub-items with TM unique characteristics.The items pertain to the development methodology (22 items),
Overview of diseases and symptoms (6 items), Recommendations
(4 items), Implementation and dissemination (5 items) and
Appendix (3 items, e.g., glossary and references) [Table 3]. We
strongly recommend developers to use the checklist (Yes or No)
with the PRIDE-CPG-TM explanation and elaborate when writing
reports of CPGs.
3.1. Domain 1. Development methodology
The development methodology comprises 22 items of examination
and focuses on describing the essential methodological elements in
CPG development.
Item 1. Title
The developer of CPGs must use terms such as ‘CPGs’ or
‘guideline’ in the title to ensure it is easy to determine that the
Table 2
Characteristics of the included clinical practice guidelines for the extraction of examples.
Condition [ref] Publication
Year
Coverage
area
Developer Target users Developing
method
Included TM intervention
Hwa-byung [19] 2013 TM KSONHR KMD EBM AT, HM, Moxa, etc.
Knee pain [21] 2013 TM KAMMS KMD EBM AT
Low back pain [22] 2013 TM KAMMS KMD EBM AT
Neck pain [20] 2013 TM KAMMS KMD EBM AT
Atopic dermatitis [25] 2014 TM KIOM KMD EBM AT. HM, PA, Moxa, Cupping, etc.
Bell's palsy [23] 2014 TM KIOM KMD EBM AT. HM, PA, Moxa, Cupping, etc.
Lumbar HIVD [24] 2014 TM KIOM KMD EBM AT. HM, PA, Moxa, Cupping, etc.
Shouler pain [29] 2015 TM KIOM KMD EBM AT, HM, EA, WA, FNA, NNA, PA, Chuna, Cupping, Moxa
Ankle sprain [30] 2015 TM KIOM KMD EBM AT, HM, EA, FNA, chuna, tapping therapy,
physiotherapy
Low back pain [28] 2009 CM and TM NICE KMD and
WMD
EBM AT
Headache [18] 2012 CM and TM NICE KMD and
WMD
EBM AT
Irritable bowel syndrome
[17]
2008 CM and TM NICE KMD and
WMD
EBM AT, HM
Diabetes [27] 2010 CM and TM SIGN KMD and
WMD
EBM AT
Chronic pain [26] 2013 CM and TM SIGN KMD and
WMD
EBM AT, HM Aromatherapy, Homeopathy
AT: Acupuncture; CPG: clinical practice guideline; CM: conventional medicine; EA: electroacupuncture; EBM: evidence based medicine; FNA: Fire-needle acupuncture;
HIVD: Herninated Intervertebral Disc; HM:, Herbal medicine; KAMMS: Korean Acupuncture & Moxibustion Medicine Society; KIOM: Korea Institute of Oriental Medicine;
KMD: Korean medicine doctor; KSONHR: The Korean Society of Oriental Neuropsychiatry, Hwa byung Research Center; Moxa: Moxibustion; NICE: National Institute for
Health and Clinical Excellence; NNA: Needle-knife acupuncture; PA: Pharmacopuncture; SIGN: Scottish Intercollegiate Guidelines Network; TM: traditional medicine; WA:
Warm-needle acupuncture.
Table 1
Characteristics of the referred methodology handbook for the extraction of items.
Study title (year)
[ref] Country
Publication
type
Publisher Checklist Included or
not
AGREE II(2010) [11]a
Canada
Book/Journal AGREE collaboration Yes
Guideline manual(2012) [13]
UK
Book/Journal NICE No
Guideline manual(2014 update) [15]
Scotland
Book/Journal SIGN No
Development of Treatment Guidelines for Evidence-based Traditional Medicine
(2004) [12]
America
Journals WHO/WPRO No
Guidelines 2.0(2014) [16]
Canada
Journal McMaster University GRADE Centre. Yes
Clinical Practice Guideline Development Manual(2013) [14]
American
Journal American academy of Otolaryngology –
Head and Neck Surgery
No
STARIGs(2011) [10]
Korea
Book National Evidence-based Healthcare
collaborating Agency
No
AGREE: appraisal of guidelines for research and evaluation; NICE: National Institute for Health and Clinical Excellence; SIGN: Scottish Intercollegiate Guidelines Network;
GRADE: The grading of recommendations, assessment, development and evaluation; STARIGs: STAndard Reporting Items for clinical practice Guidelines; WHO/WPRO: the
World Health Organization Western Paciﬁc Regional Ofﬁce.
a Evaluation tool of CPG.
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included, such as the name of the disease discussed in the CPG
(e.g., low back pain, depression or with a speciﬁc pattern
identiﬁcation), category (e.g., diagnosis or treatment), inter-
vention (e.g., acupuncture, herbal medicine or combining), and
medical environment (e.g., primary medical care or secondary
medical care) to ensure users more easily comprehend the key
information.
Item 2. Summary
The developer of CPGs should present the key information in a
summary that is centred on major recommendations to ensure
the user may easily obtain the CPG of interest. The summary
should comprise the background and method of the CPG
development, as well as the recommendations of correspond-
ing key questions. Furthermore, it may also be made into abooklet to ensure users may easily access it. Moreover, because
it plays an important role in the CPG’s dissemination and
utilisation strategy, it should be composed of key information.
Item 3. Objective
The general objective of the CPG must be clearly described in
detail. The target of the CPG (e.g., patients or general public),
sanitary objective (e.g., prevention, screening inspection,
diagnosis, or treatment), and expected beneﬁt or result should
be included.
The CPG should include the potential inﬂuence that may reach
individual health or the medical world, and the expected health
related beneﬁts should be shaped into clinical questions or
classiﬁed into different subjects. PIPOH (Population, Interven-
tion, Professional, Outcomes, and Health care settings) may be
used for shaping.
Table 3
Proposed Elaboration of domain 5 for reporting clinical practice guidelines of traditional medicine.
Item
No.
Domain/Items Description AGREE II
Item No.
Development methodology
1 Title Create a title using “clinical practice guidelines”, “category (diagnosis or treatment)” or “disease
name or with a speciﬁc pattern identiﬁcation” to clarify that the publication is a CPG.
1
2 Summary Summarise and state key information from recommendations for easy access to contents of the CPG. 19
3 Objective Specify the purpose of the CPG, clearly determine the area covered, and state the established purpose. 1
4 Necessary State the reasons why each respective CPG is necessary from various perspectives (for example, TM theory,
the size of the problem, the severity of the problem, and the public interest).
4
5 Target population Clearly specify the population group for which the therapeutic interventions of the respective disease
covered by the CPG apply (if possible, with a speciﬁc pattern identiﬁcation).
5
6 Target users Specify the group of subjects (physicians or ordinary individuals) expected to use the CPG. 6
7 Existing CPGs State the progress of domestic and overseas CPG studies regarding the respective diseases and symptoms. 1
8 Limitations State the limits and problems that arose in the CPG development process.
9 Key questions Select and state key questions for inclusion in the CPG based on the PICO format. 2
10 Evidence search and collection Specify how to search and collect evidence for each database used in the literature search. 7
11 Evidence selection criteria State information regarding how appropriate literature was selected for key questions through a standard of
selection and exclusion.
8
12 Risk of bias assessment State how the internal validity of the estimated intervention effects was assessed in the development study. 9
13 Quality of evidence State the grade and meaning of the evidence level used in the CPG. 9
14 Grade of recommendations State the grade and meaning of the recommendation system used in the CPG. 10
15 Agreement for
recommendations
State how the mutual agreement method for recommendations was ofﬁcially or unofﬁcially established. 10
16 Development process Speciﬁcally describe the development and publication processes of the CPG. –
17 CPG committee formation State the name, profession and role in the CPG of members of the CPG development organisations (Steering
Committee, Development Committee, and Review Board).
4
18 Peer review process State the peer review procedure and collected opinions to verify the overall validity of the CPG. 13
19 Formal approval State the contents ofﬁcially approved by a specialised group or agency related to the CPG. –
20 Development fund Clearly state the impact on the CPG funding sources and development procedures. 22
21 Declaration of conﬂicts of
interest
State the method of handling the interests of developers and the processing results. 23
22 Evidence updating plan Speciﬁcally state the timeframe and relevant information regarding the future renewal plan. 14
Overview of diseases/symptoms
23 Deﬁnition of disease Provide the simpliﬁed deﬁnition of each disease for users. –
24 Epidemiology State the prevalence and incidence rate of the respective disease based on the statistical data. –
25 Risk factors State the risk factors of the respective disease. –
26 Diagnostic criteria State the Korean traditional medical diagnosis (pattern identiﬁcation and classiﬁcation) of the respective
disease (e.g., clinical classiﬁcation), as well as the Western medical diagnostic criteria for reference.
–
27 Existing treatment Speciﬁcally state the previous treatment methods and assessment criteria of the respective disease. –
28 Prognosis State the progress and prognosis data of the respective disease. –
Recommendations
29 Body of quality of evidence Present body of quality of evidence and details of the contents regarding the generalisation and analysis
of the evidence of major result variables to derive recommendations (for example, general evidence
table and meta-analysis).
9
30 Recommendations Speciﬁcally and accurately grade the recommended facts regarding key questions of intervention (Herbal
medicine, acupuncture, and other options of traditional medicine treatment).
12,15,17
31 Alternative therapies Propose other interventions in addition to the predominately recommended acts in speciﬁc circumstances,
as well as the recommendations or respective evidence in the CPG.
16
32 Health beneﬁts, sides effects
and risks
State the health beneﬁts, side effects or risk factors considered to derive the recommendations. 11
Implementation and dissemination
33 Algorithm Propose the step-by-step decision-making support system (algorithm) for the diagnosis and treatment
based on the derived recommendations of the CPG.
34 Resource implications when
applying recommendations
State whether additional resources are necessary to apply the derived recommendations. 20
35 Supervision of the performance
degree of the CPGs and the
presentation of the evaluation
criteria
State the supervision or assessment plan for the degree of execution following the development of
the CPG.
21
36 Implementation tools State how to propagate and supply the CPG. 19
37 Obstruction factors and
Promotion factors
State the expediting or hindering factors that may affect the clinical application of the recommendations
in the CPG.
18
Others
38 Terminology State the deﬁnitions of terms and abbreviations that require understanding of the CPG. –
39 Reference Organise and state references of all data used in the CPG. –
40 Appendix State detailed contents in an appendix if necessary. –
AGREE: the appraisal of guidelines for research and evaluation; CPG: clinical practice guideline; PICO: patient (population, intervention, control, outcomes).
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The necessity of the CPG should be described to ensure that the
user understands the background and reason for the CPG
development with TM theory. The reason for developing the
corresponding CPG should be clariﬁed from various viewpoints
(e.g., the magnitude of the problem, the severity of the problem,
or social interest). In cases of CPG renewal, the reason for the
necessity of the renewal, as well as the newly added and
changed clinical evidence compared with the previous CPGs
should be clearly stated.
Item 5. Target Population
The CPG should clearly describe the target population (e.g.,
patient or general population). The contents should be
presented according to age, gender, clinical characteristics,
and accompanying diseases, as well as the contents of the
excluded group. If possible, it is necessary to identify the
diagnostic criteria of disease with a speciﬁc pattern identiﬁca-
tion regarding population.
Item 6. Target Users
The objective user of the CPG should be precisely described.
Thus, users for health setting and individuals who will perform
the interventions in CPG. The user may include, for example,
medical personnel, patients, guardians, and policy decision-
makers, and the scope of the included contents of the
corresponding CPG may differ according to the user. The users
may easily conﬁrm whether the data are relevant to them
through clear description.
Item 7. Existing Domestic and Foreign CPGs
It should be veriﬁed whether a domestic or foreign CPG has
been developed for the corresponding disease. It may be
identiﬁed through domestic and foreign CPG databases in
operation and through researching related academic societies.
Through the identiﬁcation of existing CPGs, the development of
CPGs based on adaptation methodology may be considered. It
would be beneﬁcial for users to orientate readers-a brief
introduction on existing CPGs for the corresponding disease.
Item 8. Limitations
The limitations of the CPG in the process of drawing the
recommendation (e.g., lack of evidence or heterogeneous
nature of evidence) should be described. The difﬁculties in
drawing evidence and the current situation of evidence used in
integrating different evidence should be described. Additional-
ly, the recommendations of CPG are not applied to all clinical
situations, and it is appropriate to describe the fact that the TM
medical environment and the clinical judgement of medical
personnel must be considered.
Item 9. Selection of Key Questions
The selection of key questions is the most important part of the
CPG, which describe the clinical questions that should be
included in the CPG. The developer shapes the necessary
contents for treating the corresponding disease with clinical
questions in the form of P (Population), I (Intervention), C
(Control), and O (Outcomes). Specially, it is necessary to explain
the questions with TM theory. The CPG may be more applicable
if clinical questions are drawn from previous in-depth meetings
of experts or via formal methodology (e.g., Delphi) to ensure the
contents are indispensable. Additionally, the clinical questions
should comprise a detailed form that may be used to issue
recommendations simply and clearly [31].Item 10. Evidence Search and Collection
The database judged to be necessary for a comprehensive
literature search should be selected and described. Informa-
tion related to the topic should be collected and complied in
the ancient and modern medical literature. The search
strategy should be speciﬁcally described to enable it to be
repeatable, and it should be organised as an appendix for easy
recognition. Through this process, users may verify whether
the literature suitable for the scope and key questions of the
CPG has been systematically searched. Speciﬁcally, there are
limits in searching TM related literature general databases;
therefore, the search engine must include the Korea medicine,
Chinese medicine, Kampo as well as other East Asian
traditional medicine databases, such as the Oriental Medicine
Advanced Searching Integrated System (OASIS) and the Korean
Traditional Knowledge Portal, as well as major Chinese
traditional medicine databases, such as China National
Knowledge Infrastructure (CNKI), Wanfang and VIP. A manual
search of journals related to the corresponding disease is
recommended.
Item 11. Evidence Selection Criteria
The inclusion and exclusion criteria applied in common for the
clinical question should be described. Based on the study
design where treatment targets on diseases with pattern
identiﬁcation and TM interventions should be specify. The
literature selection must be independently conducted by at
least two researchers. The presentation of the PRISMA ﬂow
chart facilitates user understanding of the literature selection
process [32].
Item 12. Risk of bias assessment
The names of the tools used in the evaluation of the quality of
literature, as well as the method of evaluation should be
described. The evaluation of the literature quality is referred to
as the risk of bias assessment, and the reason for this
assessment is because the effect of the intervention may be
underestimated or overestimated. The evaluation of the quality
of the corresponding literature includes the Assessment of
Multiple SysTemAtic Review (AMSTAR) for SRs and meta-
analyses [33], the Risk of Bias (ROB) for RCT [34] and the Risk of
Bias Assessment tool for Non-randomized Study (RoBANS) for
non-RCTs [35]. There are various tools used to evaluate the
literature; thus, the proper tool for the characteristic of the
literature should be used for evaluation.
Item 13. Quality of Evidence
The quality of evidence in CPG is the degree of certainty of the
effect of an intervention based on current grounds [36]. In line
with progress in CPG development, various scales and rating
schemes for the quality of evidence. The schemes for rating
quality and meaning of the evidence used in the CPG should be
described. Moreover, the intensity and limitation of the
evidence should be emphasised. The opinions on the evidence
collected for every study should be presented, and the risk of
bias or the outcome of primary studies should be described, as
well as the fact that they are evaluated with formal or informal
tools/methods. A table that refers to the different quality ranges
or an indication of whether formal tools (e.g., GRADE) are used
should be presented [37] and discuss the applicability of quality
of evidence in TM.
The CPG developers need to be cautious on recommending
evidence grading system for TM. It is well acknowledged
evidence base for many TM practice is weak or controversial –
according to the standards to western pharmaceuticals. There is
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such that best available evidence could guide practice.
Through the grade and meaning of the quality of evidence, an
individual may easily judge the multitude of the evidence of
interest, the intensity, and the magnitude of the effect.
Item 14. Grade of Recommendation
The grade of recommendation is the recommended best
practice based on the clinical experience of the CPG develop-
ment group, namely, the degree of assurance is more of an
expected result than a negative result when an intervention is
performed for a patient [38]. The grade and meaning of the
grading system used for the recommendations in the CPG
should be described. Thus, a clear explanation of the grading
system should be presented to ensure the user of the CPG
precisely understands the meaning and intensity of the
recommendations.
Item 15. Agreement of Recommendation
The method of drawing agreed recommendations must be
stated. The method used to produce the recommendations and
how the ﬁnal recommendation grade was reached should be
described, as well as the speciﬁc method of solving disagree-
ments. Formal methods of drawing an agreement include the
nominal group technique (NGT), Delphi, RAND, and meetings
for drawing an agreement. When using informal methods of
drawing an agreement (e.g., advisory conference or research
team meeting), it should describe how disagreements are
resolved. Using this approach, the user may comprehend the
rationality of the process of drawing recommendations and the
agreed level of the recommendations. Especially in cases in
which there is a lack of concrete evidence for the CPG, drawing
the recommendation grade through a formal agreement
method is a point that should be seriously considered. The
consensus method comprises a basic method for developing
CPGs in TM and requires further normalisation because of
insufﬁcient or conﬂicting evidence from high quality trials in
TM.
Item 16. Development Process
The process of developing and publishing CPGs should be
described in detail to ensure users may easily understand the
information. The process of topic selection, clinical question
selection, decisions regarding the scope and objective, the
formation of a committee, and drawing evidence and recom-
mendations should be practically described in detail.
Item 17. Guideline Committee Formation
The development group comprises a group of experts who
participate in each step of the CPGs. The name of the
development group members, academic ﬁeld/expert ﬁeld
(e.g., medical physicians, methodology expert, information
searching, or statistics), school system organisation, location,
and major role in the group should be described. The committee
is composed of the operative planning committee, which plans,
operates and manages the CPG, and the advisory committee,
which examines the general contents and counsels. This
information may be easily identiﬁed by users if presented in
diagrams and tables.
Item 18. Peer Review Process
Peer review must be conducted to verify the general validity
before the CPG is published, and the corresponding process and
method must be described. Similar to the development group
and committee, the name of the peer review group, afﬁliation,and position must be presented and must include experts of
methodology and TM clinics who are not part of the
development group or committee. The review includes general
contents, such as the objective of reviewing, method, feedback
on the recommendations, and clinical applicability, and the
enhancement of the CPG quality may also enhance the clinical
applicability.
Item 19. Formal Approval
Formal approval should be attained for the expert group or
organisation related to the developed CPG. This approval may
support the development of the CPG and become a strategy to
enhance the applicability of the publication and dissemination.
Item 20. Development Fund
Most CPGs are developed with developing funds by the
government or expert groups. The developer should plainly
describe the origin of the fund; by clearly deﬁning the role, the
inﬂuence of the interest group perspective will be conveyed.
Item 21. Declaration of Conﬂicts of Interest
The declaration of conﬂicts of interest makes public all potential
or practical conﬂicts of interest; there are situations in which
the interest conﬂicts between CPG developers, and it is
necessary to clearly state these conﬂicts. Thus, this step
elucidates the type (scope) of conﬂict of interest and minimises
potential conﬂicts of interest. The type of conﬂicting interest,
method and explanation to verify the conﬂict of interest, as well
as the measures taken to minimise the inﬂuence of the
conﬂicting interest on the development and recommendations
of the CPG should be described. The declaration of conﬂicts of
interest must be added as an appendix.
Item 22. Evidence Updating Plans
A description of how the CPG will verify new evidence and
reﬂect on it following development should be included. An
appropriate monitoring process must be incorporated for the
corresponding CPG as a renewal plan, and information and the
clear standard of the renewal time must be described.
3.2. Domain 2. Overview of diseases/symptoms
The overview of diseases/symptoms describes the main contents
regarding the deﬁnition and symptoms of the corresponding disease,
aetiology and pathology, epidemiology, Eastern/Western medical
classiﬁcation, risk factors, existing treatment modalities, progress and
prognosis to facilitate user understanding of the general disease
diagnosis and treatment.
Item 23. Deﬁnition of the Disease
The deﬁnition, symptoms, aetiology, pathology and general
contents related to the corresponding disease should be
described. This information may increase user understanding.
Item 24. Epidemiology
The prevalence, incidence, management, and economic burden
should be described based on the newest study results related
to the disease through major databases in the country.
Item 25. Risk Factor of the Disease
Data regarding the risk factors of the corresponding disease,
such as age, occupation, heredity, drinking, smoking, hyperten-
sion, hyperlipidaemia, and diabetes, and associated diseases
should be described.
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The diagnostic criteria of the related disease, such as the pattern
(syndrome), diagnosis and constitution, as well as references in
the CPG should be presented. Additionally, the presentation of
the diagnosis may facilitate user understanding.
Item 27. Existing Treatment
The existing treatment modality should be described. Herbal
medicine, acupuncture, moxibustion, cupping and any other
treatment intervention should be described in detail, and the
related rating scale should be introduced. Furthermore, reliable
quoted papers on the existing treatment method (reference
textbook or existing literature) should be added. The current
conventionally used treatment method, such as medication or
nonpharmacological therapy, should be described, and the
previously published CPGs may be referred to.
Item 28. Prognosis
Research material regarding the natural progress, prognosis,
mortality, complications, and improvement of motor distur-
bances should be described.
3.3. Domain 3. Recommendations
Recommendations cover the existing evidence analysis for drawing
the corresponding recommendations and the recommendation grade
system and emphasises that the recommendation and its supporting
evidence should be systematically connected.
Item 29. Body of quality of evidence
The developer should describe the method of putting together
all evidence on the major outcome variables for drawing the
recommendations (e.g., evidence table or meta-analysis).
Various types and levels of studies exist for speciﬁc clinical
questions, and the study results may vary. It is proper to
describe how the evidence is summarised and put together, as
well as to indicate the tools used in this process. Speciﬁcally, the
TM or CAM intervention is various and unique. If applicable, it is
necessary for the acupuncture recipe and HM regime in each
evidence; however, we cannot ﬁnalize the standard treatment
method. We suggest TM CPG developers using the reporting
guidelines for sufﬁcient description of TM intervention when
summarize the primary study [9,39–41]. And then TM CPG
developers should discuss how to incorporating TM diagnostic
methods in decision making, sufﬁcient description on herbal
medicine, acupuncture and other treatment that allow replica-
tion by CPG users, as well as herb drug interaction. Finally, the
developer should select the quality of evidence according to the
schemes for rating quality of evidence deﬁned at item 13.
Item 30. Recommendations
The recommendations comprise descriptions of the recom-
mended actions for speciﬁc situations of the target population,
and the standard factors used to assess and analyse the related
information to reach these recommendations must be speciﬁ-
cally and clearly described as the analytical framework.
Recommendations should be centred on indispensable clinical
questions in the treatment of patients with the diagnosis,
examination, treatment start time, treatment intervention (e.g.,
TM treatments, including herbal medicine, acupuncture,
moxibustion, or tuina), and evaluation method of the corre-
sponding disease. Moreover, the contents of the recommen-
dations should be easy to identify. The recommendations and
their supporting evidence must be clearly related. Major
recommendations may be easily comprehended by users ifsummarised in a separate textbox or written in bold or
underlined.
Item 31. Alternative Therapies
If there are alternative interventions that may be selected in
addition to the primary recommended therapy in speciﬁc
situations, these interventions should be presented with the
recommendations or the corresponding evidence in the CPG.
Item 32. Consideration for Health Beneﬁts, Adverse Events, and
Risk Factors
When making recommendations for CPG, the health beneﬁts,
adverse events and risk factors must be considered. Thus,
discussions regarding the general effectiveness related to the
various ﬁnal outcomes may be included. There must be
evidence that the CPG considered the debate over the health
beneﬁts, such as the survival rate and quality of life, and the
harm, such as adverse events.
3.4. Domain 4. Implementation and dissemination
Implementation and dissemination comprise ﬁve items that
present the ﬂow chart of the decision making steps and request the
presentation of the necessary information (e.g., guidelines for the
patient, simple guidelines, and summary) for the implementation and
dissemination of the CPGs.
Item 33. Algorithm
An algorithm represents the systematic and phased presenta-
tion of the decision making process in the form of a ﬂow chart of
the recommendations, which facilitates the decision making of
patients and physicians in the clinical ﬁeld. It may easily inform
the user of the CPG with the recommendations of the
corresponding disease. Development group will show the
process from Pattern identiﬁcation diagnosis to treatment
based on recommendation regarding targeted populations.
Item 34. Resource Implications When Applying Recommenda-
tions
The potential resource implications from the recommendations
should be described. Additional resources may be necessary for
the recommendations to be applied. For example, professional
medical personnel, new equipment, and costly medications
may be included.
Item 35. Supervision of the Performance Degree of the CPG and
Presentation of the Evaluation Criteria
If necessary, the speciﬁc clinical auditing and evaluation
standard must be presented for the clear clinical outcome
scale drawn from the key recommendations of the CPG. This
may become important basic data for the upcoming establish-
ment of the dissemination strategy of the CPG, as well as
increase the application of the CPG.
Item 36. Implementation Tools
The presentation of the implementation tools may represent a
major tool for increasing the implementation and practicality of
the CPG in TM. Implementation tools include patient guidelines,
simple guidelines, and summaries, as well as posting on
websites or publishing. Specially, implementation strategy
dependent on TM healthcare system in each country. Generally,
the implementation model is used as organizing framework
where the rate and extent of adoption of CPGs are inﬂuenced by
the nature of the CPG and how it is communicated to TM
clinician.
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Obstruction factors and promotion factors may exist that
inﬂuence the application of the recommendations of the
CPG. The lack of evidence for drawing recommendations in
the development process of CPG may become the most
inﬂuential factor in the dissemination and application. This
may present the necessary topic in the research and
development of speciﬁc clinical ﬁelds and is one important
function of a CPG.
3.5. Domain 5. Others
Others is the section in which the deﬁnition of terms used in the
CPG, references, and appendix are provided.
Item 38. Terminology
Considering the understanding of the CPG users, the deﬁnitions
and abbreviations of terms in the CPG that require explanation
should be presented, which thereby facilitates user under-
standing and correct application of the CPG.
Item 39. References
The user should be able to identify related references by
describing all literature included in the development of the CPG
as evidence in the References
Item 40. Appendix
The search strategy, declaration of conﬂict of interest, and
reference tools are presented as appendices.
4. Discussion
Our previous study comprised an appraisal of the quality of
reporting in TM trials in Korea and demonstrated that the quality
was poor [42,43]. It appears that the quality of trials was improved
after adapting the reporting guideline. Reporting guidelines for the
development of CPG in TM can be utilized by TM experts who have
difﬁculty in ﬁnding a good methodology for developing CPG. Thus,
we determined that the endorsement of reporting guidelines is
also required for CPG in TM.
The speciﬁc goal is as follows. First, CPG developers for TM
should develop high quality CPGs by easily understanding and
referring to them. Second, a stable medical service should be
provided to individuals with an accurate diagnosis, including an
effective therapy method, via the development of high quality
CPGs for TM. Third, understanding of evidence-based CPG should
be increased through the development of CPGs for TM, which
thereby advances TM. Furthermore, the guidance of reporting of
CPGs for development is also required. The quality of CPGs for TM
in Korea and China has remained suboptimal according to the
AGREE II instrument evaluation because most CPGs for TM are
based on expert consensus or appear similar to textbooks [44–46].
Therefore, CPG developers in TM areas should exert greater efforts
to ensure high-quality CPGs based on EBM.
We identiﬁed 7 methodology guidelines for CPG developers
that focus on how to address the CPGs in TM. In all, 40 items were
extracted, as well as proper examples from 12 guidelines.
Following a qualitative analysis, 5 domains were identiﬁed, which
includes development methodology, Overview of disease/symp-
toms, Recommendations, Implementation and dissemination and
others. The items included in the PRIDE-CPG-TM are composed to
adhere to the methodological quality and clarity in the develop-
ment of evidence-based CPG through the examination process by
CPG experts.Finally, we developed the PRIDE-CPG-TM to promote explicit
and comprehensive reporting of CPG for TM. The guide book
consists of items speciﬁc to reporting CPGs and precludes generic
criteria that are applicable to all CPGs in TM areas. In addition, this
guidance should be used for referencing the description method
and development methodology by informing CPG groups in TM
when developing CPGs, as well as educating the CPG development
groups.
Carefully planned and well-executed CPGs provide the best
estimates of treatment effects and may thus guide decision
making; however, trials that lack methodological rigor cause over
or underestimation of treatment effect sizes as a result of bias or
confounding factors. Thus, many efforts have been undertaken to
improve the production of evidence or reporting of evidence-based
CPGs for TM. Therefore, this study is critical to cover the
characteristics of TM and follows the rules of EBM. The 40 items
also included are numbered in the order to be described when
developing CPGs and are user friendly. However, the order of the
description composition may be changed according to the
environment of the developers. The checklist will be to promote
complete and transparent reporting among CPG developers and
indirectly improve the rigor, comprehensiveness and credibility of
the development of CPGs.
Examples were presented by partially extracting contents
judged to be appropriate from high quality domestic and foreign
CPGs and are mainly composed of examples associated with TM or
CAM. The original article of the corresponding CPG is recom-
mended for reference when verifying the speciﬁc content
described in the example.
However, the awareness of EBM comprises a major problem,
and individuals require training on how to interpret the evidence.
Most important is the identiﬁcation of the gap between the
evidence and practice.
The key points for TM developers to remember are as follows:
TM is the integration of physician experiences of successive
dynasties. Physician experiences of successive dynasties are not
only the essence of TM but also the basis, the core, and the
characteristic of the evidence-based CPG of TM. However, how
ancient and modern physician experiences were abstracted and
integrated into the evidence-based CPG of TM remains a research
hotspot and a difﬁculty in the development of evidence-based CPG
of TM [47]. Therefore, CPG developers in TM harmonised the
scientiﬁc evidence via SRs, as well as clinical expert experiences
using formal consensus Delphi or RAND methods. Thus, a
consensus process of clinical evidence should be crucial charac-
teristic of drawing the quality of evidence. Unique area to TM have
the epistemological difference between TM practice and the
philosophy of EBM (i.e. balancing the clinical reality of individual-
ized treatment in TM practice and standardizing required by EBM).
Specially, how to incorporating the diagnostic methods (i.e. pattern
identiﬁcation) in decision making have to be considered. Other
considerations beyond the evidence are therefore needed to
formulate speciﬁc and applicable recommendations for clinical
practice.
These guidelines have several limitations. The PRIDE-CPG-TM is
only for De Novo processes. Even though, several guidelines have
been developed; evidence-based CPG in TM ﬁelds remain in the
initial stage. Thus, when TM researchers develop CPGs, there are no
CPGs to use as adaptation tools. Therefore, to the best of our
knowledge, the TM ﬁeld has no choice but to develop the De Novo
process because it not only lacks quality CPGs in TM but is also only
based on a consensus of expert opinions. Second, we aimed to
identify all characteristics of TM areas to develop the CPGs with
multidisciplinary expert. However, we are not certain this aim was
accomplished because do not use of Delphi method. Thus, we
invite comments regarding PRIDE-CPG-TM to improve it. In the
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Despite these limitations, this study is useful because it is the
ﬁrst description of reporting items for CPGs available in TM.
Therefore, PRIDE-CPG-TM are valid reporting guideline. However,
we can not specify acceptable methodology information in TM how
to discuss or ﬁnalize the each item due to each items have many
issues. The PRIDE-CPG-TM has a focus only on the reporting of the
CPG in TM.
There are several recommendations for the future. Firstly,
specialists will be fostered and subsequently spread or distribut-
ed through regular CPG education for the development of CPGs in
TM and the health care industry, based on the expertise acquired
from a group of experts. With the application of the rationale of
medical technology assessment, TM is subjected to the decision-
making process to a considerable extent in the health care policy
system. This may also apply to an actual clinical setting, which
may be followed by an increased accessibility to TM. Moving
forward, a methodology for medical treatment services in TM
should be established based on the development of evidence-
based CPG, as implemented. Thus If PRIDE-CPG-TM are to be
useful and more widely disseminated, we need to be developed
using robust and widely accepted methodology in TM. Moreover,
this progress should be followed by various studies and research
activities that will promote the propagation and pursuit of the
development of evidence-based CPG. The current lack of
appreciation on the epistemological difference between TM
and western medicine has made the “guideline” approach highly
problematic. Currently clinical research method is yet to embrace
the holistic features in full. The cook book medicine problem has
been heavily criticized in western medicine and we believe this
problem would remain when attempts are made to “standardize”
TM – of which different schools of thoughts are highly prevalence
across different system.
With the development of evidence-based CPG for TM, it will
become possible to objectively judge the current evidence in the
TM ﬁeld. Thus, it would also be connected to the exploration of
clinical research areas for which clinical support may be required.
Speciﬁcally, regarding the lack of evidence, decisions as to what
and how research evidence should develop must be determined.
Therefore, TM researchers must exert effort to research evidence-
based approaches and subsequently input them in clinical
practice.
In conclusion, CPGs should be based on the best available
evidence. However, the evidence in TM is often incomplete,
controversial, or lacking. This study aimed to provide evidence and
recommendations for both TM clinical physicians using a
methodology that is appropriate for the current status of TM
characteristics, which lacks clinical evidence. Therefore, the PRIDE-
CPG-TM has a value to suggest a de novo guidance for the
development of CPG in TM. As a matter of fact, TM often fails to
show clinical evidence of high quality even though it successfully
provides good treatment value. Before applying AGREE or EB based
CPG, it is very convenient for TM experts to develop CPG using this
PRIDE-CPG-TM that this article suggests. Thus, this article can be
able to be utilized by TM experts who feel difﬁculty to ﬁnd a good
methodology to develop CPG and aid the clear reporting.
Furthermore, PRIDE-CPGs-TM can be extended to EB-CPGs-TM
in the near future with international multidisciplinary group. We
hope this study can facilitate the development and publication of
high quality CPGs for TM.
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